| P2093 | author name string | Brade WP | |
| | Herdrich K | |
| | Araujo CE | |
| | Kachel-Fischer U | |
| P2860 | cites work | Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma | Q28299143 |
| | Ifosfamide, Fanconi's syndrome, and rickets | Q28321377 |
| | Dana-Farber Cancer Institute studies in advanced sarcoma | Q28329197 |
| | Inappropriate antidiuretic hormone secretion induced by ifosfamide | Q28330067 |
| | Ifosfamide with mesna uroprotection in the management of lung cancer | Q28330300 |
| | Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor | Q28330594 |
| | Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion | Q28332349 |
| | Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders | Q28333410 |
| | Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors | Q28335745 |
| | Phase I clinical trial of isophosphamide (NSC-109724) | Q28336843 |
| | Severe renal failure following high-dose ifosfamide and mesna | Q28340718 |
| | Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector | Q28341314 |
| | Mesna excretion and ifosfamide nephrotoxicity in children | Q28341528 |
| | Studies on the human pharmacokinetics of isophosphamide (NSC-109724) | Q28342614 |
| | Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma | Q33391619 |
| | Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. | Q33393062 |
| | Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer | Q33393064 |
| | Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer | Q33393066 |
| | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group | Q33394685 |
| | Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer | Q33396007 |
| | Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer | Q33397038 |
| | Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide | Q33406313 |
| | A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer | Q33406315 |
| | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study | Q33416899 |
| | Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study | Q33417157 |
| | Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). | Q33419201 |
| | A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer | Q33427498 |
| | Unexpected toxicity in patients treated with iphosphamide | Q33464726 |
| | Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. | Q33484836 |
| | Mesna--a short review | Q34166616 |
| | Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism | Q34357399 |
| | The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients | Q34358280 |
| | The effect of age on the pharmacokinetics of ifosfamide | Q34630267 |
| | Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds | Q34713023 |
| | Hypophosphataemic rickets after ifosfamide treatment in children | Q35713092 |
| | Cisplatin nephrotoxicity. A review | Q38730217 |
| | Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial | Q39243736 |
| | Ifosfamide | Q39642917 |
| | Ifosfamide--pharmacology, safety and therapeutic potential | Q39827086 |
| | A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report | Q40763628 |
| | A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor | Q40780826 |
| | Toxicity of high-dose ifosfamide in children | Q40781065 |
| | Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study | Q40807044 |
| | Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer | Q41201962 |
| | Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma | Q41201971 |
| | Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer | Q41864850 |
| | Ifosfamide encephalopathy: a reappraisal | Q42199685 |
| | Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors | Q42200565 |
| | Fanconi syndrome after ifosfamide | Q42202871 |
| | Ifosfamide-induced renal tubular defects | Q42203005 |
| | Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna | Q42207556 |
| | Prediction of ifosfamide/mesna associated encephalopathy | Q42207733 |
| | Nephrotoxicity associated with ifosfamide | Q42211330 |
| | Pharmacokinetics and bioavailability of oral ifosfamide | Q42221355 |
| | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma | Q42225887 |
| | Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity | Q42248930 |
| | Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine | Q42259368 |
| | Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds | Q42270328 |
| | Irreversible encephalopathy with ifosfamide/mesna | Q42673533 |
| | Encephalopathy caused by an ifosfamide-mesna combination | Q42682152 |
| | Ifosfamide/mesna encephalopathy | Q42684346 |
| | Encephalopathy with rapid infusion ifosfamide/mesna | Q42684547 |
| | Avoiding ifosfamide/mesna encephalopathy | Q42685008 |
| | Encephalopathy associated with ifosphamide/mesna therapy | Q42686588 |
| | Acute ifosfamide-induced tubular toxicity | Q42702592 |
| | Ifosfamide-induced Fanconi syndrome | Q42702617 |
| | Bioavailability of ifosfamide in patients with bronchial carcinoma | Q43559419 |
| | Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide | Q44058478 |
| | Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma | Q44128266 |
| | Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function | Q44565289 |
| | A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma | Q44664696 |
| | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma | Q44745644 |
| | Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy | Q44777279 |
| | Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer | Q44947950 |
| | High-dose ifosfamide with mesna uroprotection: a phase I study | Q45189490 |
| | Interstitial pneumonitis associated with ifosfamide therapy | Q46954948 |
| | A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma | Q48153477 |
| | Ifosfamide by continuous infusion to prevent encephalopathy | Q49132204 |
| | Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP. | Q52507781 |
| | Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study. | Q53406934 |
| | Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children. | Q53412659 |
| | Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. | Q54323593 |
| | A study of cis-platinum and ifosfamide in alkylating agent-resistant ovarian cancer. | Q54360390 |
| | Phase II trial of ifosfamide in children with malignant solid tumors. | Q54412757 |
| | Fatal Encephalopathy with Ifosfamide/Mesna | Q57906850 |
| | Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy | Q58212582 |
| | Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide | Q58864841 |
| | Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies | Q67294274 |
| | High-dose ifosfamide and mesna in advanced breast cancer. A phase II study | Q67294285 |
| | Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease | Q67300324 |
| | Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer | Q67660418 |
| | Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma | Q67927819 |
| | Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group | Q67929138 |
| | A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma | Q67953440 |
| | Ifosfamide pharmacokinetics and neurotoxicity | Q68082516 |
| | Ifosfamide in soft tissue sarcoma | Q68367212 |
| | [Pneumo- and cardiotoxic side effects following combination chemotherapy with epirubicin and ifosfamide] | Q68460683 |
| | Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer | Q68472325 |
| | The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors | Q68487568 |
| | Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group | Q68499345 |
| | Ifosfamide and mitoxantrone (I-M) in relapsed and refractory high grade non-Hodgkin's lymphoma and Hodgkin's disease | Q68553846 |
| | [Activation of ifosfamide in man and animal] | Q68665621 |
| | The effect of route of administration and fractionation of dose on the metabolism of ifosfamide | Q68801422 |
| | Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma | Q68801471 |
| | A phase II study of ifosfamide in endometrial cancer | Q68801476 |
| | A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas | Q68801482 |
| | Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil | Q68801485 |
| | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours | Q68801487 |
| | Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines | Q68801494 |
| | Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas | Q69056912 |
| | Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer | Q69181921 |
| | Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988 | Q69188386 |
| | Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas | Q69200878 |
| | Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity | Q69203766 |
| | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy | Q69226294 |
| | Pilot study with adriamycin and ifosfamide in small cell lung cancer | Q69342291 |
| | Tubular nephrotoxicity during long-term ifosfamide and mesna therapy | Q69376791 |
| | Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial | Q69550800 |
| | An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group | Q69677732 |
| | Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy | Q69745624 |
| | Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial | Q69833940 |
| | Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma | Q69835423 |
| | [Hepatotoxicity with etoposide-ifosfamide combination therapy] | Q69851459 |
| | Ifosfamide, mesna, and encephalopathy | Q69864897 |
| | Dechloroethylation of ifosfamide and neurotoxicity | Q69889353 |
| | Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein | Q69891184 |
| | Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma | Q69936079 |
| | Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas | Q70062030 |
| | Ifosfamide/mesna and hematuria | Q70366208 |
| | Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas | Q70409184 |
| | Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma | Q70451163 |
| | High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial | Q70451176 |
| | High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma | Q70451258 |
| | Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test | Q70797964 |
| | Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation | Q71532791 |
| P921 | main subject | ifosfamide | Q418560 |
| | mesna | Q424997 |
| P304 | page(s) | S164-86 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Dosing and side-effects of ifosfamide plus mesna | |
| P478 | volume | 117 Suppl 4 | |